Clinical Trials

40 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07472478 2026-03-16

GIVEN

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04302025 2026-03-06

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

99 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT07425795 2026-02-23

Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

36 enrolled

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07408635 2026-02-13

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

43 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07398937 2026-02-10

ECTOP-1036

116 enrolled

Lung Neoplasms

NCT06610734 2026-02-09

SKY

202 enrolled

Small Cell Lung Cancer Extensive Stage

NCT06738160 2026-02-06

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

27 enrolled

NSCLC

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

25 enrolled

Small Cell Lung Carcinoma

NCT07330596 2026-01-09

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02153229 2025-12-26

MPM-PDT

Other solid neoplasmThoracic

52 enrolled

Epitheliod Malignant Pleural Mesothelioma

NCT07293247 2025-12-22

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

164 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

240 enrolled

First-line Advanced NSCLC Patients

NCT06102057 2025-12-17

PACCELIO

110 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07288034 2025-12-17

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

535 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Lung Neoplasms

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05775796 2025-10-01

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06784791 2025-08-29

NEOpredict-EGF

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07139041 2025-08-24

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled

NSCLC

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

243 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT05691829 2025-07-29

IRRADIATE-Lung

19 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06947694 2025-07-22

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

427 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07069270 2025-07-16

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

28 enrolled

Small Cell Lung Carcinoma

NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

36 enrolled

Unresectable Non-small Cell Lung Cancer

NCT06953843 2025-07-14

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

366 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT07035392 2025-06-25

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

32 enrolled

Adebrelimab (SHR-1316)

NCT07034391 2025-06-24

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04905316 2025-06-17

CHORUS

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04952480 2025-06-12

DARTS

31 enrolled

Small Cell Lung Carcinoma

NCT02122185 2025-06-08

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

110 enrolled

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Pleural Effusion, Malignant

NCT06978153 2025-05-18

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

66 enrolled

Limited Stage Small Cell Lung Cancer

NCT05742607 2025-05-16

MATISSE

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

1 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06946836 2025-04-27

Neoadjuvant

80 enrolled

Resectable Non-small Cell Lung Cancer

NCT06939127 2025-04-22

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04997382 2025-02-25

CLASSIC5

Phase 2 Completed

112 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04364048 2024-12-20

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

10 enrolled 10 charts

Lung Neoplasms

NCT06718309 2024-12-05

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

45 enrolled

Lung Neoplasms

NCT06614231 2024-09-26

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

48 enrolled